Target Name: PLA2G4B
NCBI ID: G100137049
Review Report on PLA2G4B Target / Biomarker Content of Review Report on PLA2G4B Target / Biomarker
PLA2G4B
Other Name(s): Cytosolic phospholipase A2 beta (isoform a) | PA24B_HUMAN | CPLA2-beta | JMJD7-PLA2G4B protein | JMJD7-PLA2G4B readthrough | HsT16992 | lysophospholipase A1 group IVB | phospholipase A2 group IVB | cPLA2-beta | Lysophospholipase A1 group IVB | phospholipase A2, group IVB (cytosolic) | Phospholipase A2 group IVB | JMJD7-PLA2G4B | jumonji domain containing 7-phospholipase A2, group IVB (cytosolic) read-through | Cytosolic phospholipase A2 beta | Phospholipase A2, group IVB (cytosolic)

PLA2G4B: A Drug Target / Disease Biomarker

PLA2G4B is a protein that is expressed in various tissues throughout the body, including the brain, heart, and kidneys. It is a member of the PLA2 family of G-proteins, which are involved in cell-signaling processes. The PLA2G4B gene has been identified as a potential drug target or biomarker for various diseases, including cancer, neurodegenerative diseases, and cardiovascular diseases.

The PLA2G4B protein is involved in several cellular processes that are important for maintaining tissue structure and function. One of its key functions is to regulate the activity of integrins, which are proteins that help cells stick to the surface of other cells. Integrins are involved in many important cellular processes, including cell adhesion, migration, and invasion. PLA2G4B is thought to play a role in modulating the activity of integrins, which could make it an attractive target for drugs that are designed to interfere with these processes.

In addition to its role in cell-signaling processes, PLA2G4B is also involved in the regulation of inflammation. Inflammation is a critical response of the immune system to harmful stimuli, but it can also contribute to the development of a variety of diseases, including cancer and neurodegenerative diseases. PLA2G4B is thought to be involved in the regulation of inflammation by controlling the activity of immune cells and promoting the production of pro-inflammatory cytokines.

PLA2G4B is also involved in the regulation of cell-cycle progression, which is the process by which cells grow, divide, and replicate their genetic material. ThePLA2G4B protein is thought to play a role in the regulation of cell-cycle progression by controlling the activity of microtubules, which are important for transporting genetic material within the cell.

PLA2G4B is also involved in the regulation of cellular processes that are important for maintaining tissue homeostasis. homeostasis is the ability of cells to maintain a stable internal environment, which is critical for the survival of the cell. PLA2G4B is thought to play a role in the regulation of cellular homeostasis by controlling the activity of ion channels, which are responsible for the movement of ions into and out of the cell.

In conclusion, PLA2G4B is a protein that is involved in several cellular processes that are important for maintaining tissue structure and function. As a potential drug target or biomarker, PLA2G4B is attracting a lot of interest due to its involvement in a variety of diseases, including cancer, neurodegenerative diseases, and cardiovascular diseases. Further research is needed to fully understand the role of PLA2G4B in these diseases and to develop effective treatments.

Protein Name: Phospholipase A2 Group IVB

Functions: Calcium-dependent phospholipase A1 and A2 and lysophospholipase that may play a role in membrane phospholipid remodeling

The "PLA2G4B Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PLA2G4B comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

PLA2G4C | PLA2G4D | PLA2G4E | PLA2G4F | PLA2G5 | PLA2G6 | PLA2G7 | PLA2R1 | PLAA | PLAAT1 | PLAAT2 | PLAAT3 | PLAAT4 | PLAAT5 | PLAC1 | PLAC4 | PLAC8 | PLAC8L1 | PLAC9 | PLAC9P1 | PLAG1 | PLAGL1 | PLAGL2 | Plasma Membrane Calcium ATPase | PLAT | Platelet Glycoprotein Ib Complex | Platelet-activating factor acetylhydrolase isoform 1B complex | Platelet-Derived Growth Factor (PDGF) | Platelet-Derived Growth Factor Receptor | PLAU | PLAUR | PLB1 | PLBD1 | PLBD1-AS1 | PLBD2 | PLCB1 | PLCB2 | PLCB3 | PLCB4 | PLCD1 | PLCD3 | PLCD4 | PLCE1 | PLCE1-AS2 | PLCG1 | PLCG1-AS1 | PLCG2 | PLCH1 | PLCH2 | PLCL1 | PLCL2 | PLCXD1 | PLCXD2 | PLCXD3 | PLCZ1 | PLD1 | PLD2 | PLD3 | PLD4 | PLD5 | PLD6 | PLEC | PLEK | PLEK2 | PLEKHA1 | PLEKHA2 | PLEKHA3 | PLEKHA4 | PLEKHA5 | PLEKHA6 | PLEKHA7 | PLEKHA8 | PLEKHA8P1 | PLEKHB1 | PLEKHB2 | PLEKHD1 | PLEKHF1 | PLEKHF2 | PLEKHG1 | PLEKHG2 | PLEKHG3 | PLEKHG4 | PLEKHG4B | PLEKHG5 | PLEKHG6 | PLEKHG7 | PLEKHH1 | PLEKHH2 | PLEKHH3 | PLEKHJ1 | PLEKHM1 | PLEKHM1P1 | PLEKHM2 | PLEKHM3 | PLEKHN1 | PLEKHO1 | PLEKHO2 | PLEKHS1 | PLET1 | Plexin